Search PubMed⌕ Search

Biomedical subjects

B Bannwarth

Publications and source records attributed to B Bannwarth.

179 records · Page 10Linked to original sources
PubMedDate not supplied

Influence of sulfasalazine on established collagen arthritis in rats.

Collagen induced arthritis (CIA) in rats is an experimental model that is characterized by an erosive synovitis associated with periostitis and both peripheral and axial ossifying enthesopathy. The influence of long-term therapy with sulfasalazine (80 mg/day on weekdays) on established CIA in Wistar Furth rats was investigated. Clinical and X-ray examination showed a significant improvement in the joint lesions of the uninjected paws in the treated rats as compared to controls. This effect was, however, delayed. On the other hand, periosteal new bone formation and caudal enthesopathy (spondylodiscitis) were not altered by the treatment.

Animals↗
PubMedDate not supplied

[Determination of protein binding of drugs using equilibrium dialysis. Influence of volume displacement caused by osmotic pressure].

By the determination of the free concentration of a drug using the equilibrium dialysis method, a volume shift could be observed, inducing a dilution of the protein medium. The value of this volume shift varies with the plasmatic sample and could produce a misdetermination of the free fraction which could be important, essentially for the drugs strongly bound to proteins.

Blood Proteins↗
PubMedDate not supplied

[Pharmacokinetics of methotrexate in rheumatoid arthritis: therapeutic implications].

The fraction of oral methotrexate (MTX) absorbed averages 70 per cent at low doses (< or = 10 mg/m2), both fasting and after food. The mean binding of MTX to serum albumin is 42-57 per cent. Less than 10 per cent of MTX is oxidised to 7-OH-MTX. Furthermore, MTX is partly converted to polyglutamate derivatives which accumulate in some cells resulting in sustained efficacy of the drug in spite of its relatively short plasma elimination half-life. MTX is mainly excreted by the kidney as intact drug. Accordingly careful monitoring of renal function is justified. MTX undergoes bidirectional transport within the renal tubules leading to drug interactions. Oral, intramuscular and subcutaneous routes of administration were reported to result in comparable bioavailability. There is a marked interindividual variability in MTX disposition. Conversely, the intraindividual variability is moderate even over a long time period. Finally, no clear relationship between pharmacokinetic parameters and clinical response or toxicity has been found in patients with rheumatoid arthritis.

Adult↗
PubMedDate not supplied

[Methotrexate and non-steroidal anti-inflammatory agent combination in rheumatoid arthritis].

It is well known that methotrexate (MTX), used at high dosage in cancer patients, must not be combined with a non-steroidal anti-inflammatory drug (NSAID) because of high risk of side effects; prescribed at low dosage (< or = 15 mg per week) in rheumatoid arthritis patients, MTX is often combined with an NSAID. Some cases reported in the literature underline the potential toxicity of the association of low dose MTX with an NSAID, but most of the pharmacological studies do not confirm this hypothesis. Except for salicylates, NSAIDs do not affect the absorption, distribution, protein binding, area under the curve, half-life, or the elimination of MTX. Therefore, if necessary, MTX (< or = 15 mg per week) can be combined with an NSAID during the treatment of rheumatoid arthritis.

Anti-Inflammatory Agents, Non-Steroidal↗